drug
TREMFYA
updated 6mo agoby Janssen Biotech Inc
community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying TREMFYA
- phase1A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon
- phase3Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
- phase2A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- phase2A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
- phase3A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
- phase4A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- phase3A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- —Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis
News(10)
- Another autoimmune CAR-T death; Treasury zeroes in on China dealsA patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.biopharma_dive · 24d ago
- J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absentWhile innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.biospace · 1mo ago
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 1mo ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 1mo ago
- Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 winsSpyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.fiercebiotech · 2mo ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 3mo ago
- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsJ&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.biopharma_dive · 4mo ago
- Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pillSet to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.biopharma_dive · 4mo ago
- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testThe results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.biopharma_dive · 5mo ago
- AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…endpoints · 5mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that